Cormedix Analyst Ratings
Cormedix Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/15/2023 | 365.12% | JMP Securities | → $19 | Reiterates | Market Outperform → Market Outperform |
| 08/10/2023 | 46.88% | RBC Capital | → $6 | Initiates Coverage On | → Outperform |
| 08/08/2023 | 193.76% | Needham | $13 → $12 | Maintains | Buy |
| 06/21/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 05/19/2023 | 365.12% | JMP Securities | $16 → $19 | Maintains | Market Outperform |
| 05/16/2023 | 218.24% | Needham | → $13 | Reiterates | Buy → Buy |
| 03/31/2023 | 291.68% | JMP Securities | → $16 | Reiterates | → Market Outperform |
| 03/31/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/03/2023 | 218.24% | Needham | → $13 | Reiterates | → Buy |
| 03/01/2023 | 291.68% | JMP Securities | $14 → $16 | Maintains | Market Perform |
| 11/11/2022 | 218.24% | Needham | $12 → $13 | Maintains | Buy |
| 08/12/2022 | 291.68% | Truist Securities | $27 → $16 | Maintains | Buy |
| 08/09/2022 | 242.72% | JMP Securities | $19 → $14 | Maintains | Market Outperform |
| 08/09/2022 | 193.76% | Needham | $20 → $12 | Maintains | Buy |
| 05/14/2021 | 609.91% | Needham | $31 → $29 | Maintains | Buy |
| 02/17/2021 | 658.87% | Needham | → $31 | Initiates Coverage On | → Buy |
| 02/02/2021 | 756.79% | Truist Securities | $20 → $35 | Maintains | Buy |
| 09/29/2020 | 438.56% | JMP Securities | → $22 | Initiates Coverage On | → Market Outperform |
| 09/21/2020 | 389.6% | Truist Securities | → $20 | Initiates Coverage On | → Buy |
| 08/11/2020 | 144.8% | HC Wainwright & Co. | $14 → $10 | Maintains | Buy |
| 05/12/2020 | 193.76% | B. Riley Securities | $10 → $12 | Maintains | Buy |
| 03/18/2020 | 144.8% | B. Riley Securities | $15 → $10 | Maintains | Buy |
| 12/18/2019 | — | B. Riley Securities | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/15/2023 | 365.12% | JMP 证券 | → 19 美元 | 重申 | 市场跑赢大盘 → 市场跑赢大盘 |
| 08/10/2023 | 46.88% | 加拿大皇家银行资本 | → 6 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 08/08/2023 | 193.76% | 尼德姆 | 13 美元 → 12 美元 | 维护 | 买 |
| 06/21/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | 购买 → 购买 |
| 05/19/2023 | 365.12% | JMP 证券 | 16 美元 → 19 美元 | 维护 | 市场表现跑赢大盘 |
| 05/16/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | 购买 → 购买 |
| 03/31/2023 | 291.68% | JMP 证券 | → 16 美元 | 重申 | → 市场跑赢大盘 |
| 03/31/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | → 购买 |
| 03/03/2023 | 218.24% | 尼德姆 | → 13 美元 | 重申 | → 购买 |
| 03/01/2023 | 291.68% | JMP 证券 | 14 美元 → 16 美元 | 维护 | 市场表现 |
| 11/11/2022 | 218.24% | 尼德姆 | 12 美元 → 13 美元 | 维护 | 买 |
| 2022 年 12 月 8 日 | 291.68% | Truist 证券 | 27 美元 → 16 美元 | 维护 | 买 |
| 08/09/2022 | 242.72% | JMP 证券 | 19 美元 → 14 美元 | 维护 | 市场表现跑赢大盘 |
| 08/09/2022 | 193.76% | 尼德姆 | 20 美元 → 12 美元 | 维护 | 买 |
| 05/14/2021 | 609.91% | 尼德姆 | 31 美元 → 29 美元 | 维护 | 买 |
| 02/17/2021 | 658.87% | 尼德姆 | → 31 美元 | 启动覆盖范围开启 | → 购买 |
| 02/02/2021 | 756.79% | Truist 证券 | 20 美元 → 35 美元 | 维护 | 买 |
| 09/29/2020 | 438.56% | JMP 证券 | → 22 美元 | 启动覆盖范围开启 | → 市场跑赢大盘 |
| 2020 年 9 月 21 日 | 389.6% | Truist 证券 | → 20 美元 | 启动覆盖范围开启 | → 购买 |
| 08/11/2020 | 144.8% | HC Wainwright & Co. | 14 美元 → 10 美元 | 维护 | 买 |
| 05/12/2020 | 193.76% | B. 莱利证券 | 10 美元 → 12 美元 | 维护 | 买 |
| 2020 年 3 月 18 日 | 144.8% | B. 莱利证券 | 15 美元 → 10 美元 | 维护 | 买 |
| 12/18/2019 | — | B. 莱利证券 | 启动覆盖范围开启 | → 购买 |
What is the target price for Cormedix (CRMD)?
Cormedix (CRMD) 的目标价格是多少？
The latest price target for Cormedix (NASDAQ: CRMD) was reported by JMP Securities on November 15, 2023. The analyst firm set a price target for $19.00 expecting CRMD to rise to within 12 months (a possible 365.12% upside). 10 analyst firms have reported ratings in the last year.
JMP Securities于2023年11月15日公布了Cormedix（纳斯达克股票代码：CRMD）的最新目标股价。该分析公司将目标股价定为19.00美元，预计CRMD将在12个月内升至12个月内（可能上涨365.12％）。去年有10家分析公司公布了评级。
What is the most recent analyst rating for Cormedix (CRMD)?
分析师对Cormedix (CRMD) 的最新评级是多少？
The latest analyst rating for Cormedix (NASDAQ: CRMD) was provided by JMP Securities, and Cormedix reiterated their market outperform rating.
JMP Securities提供了Cormedix（纳斯达克股票代码：CRMD）的最新分析师评级，Cormedix重申了其市场跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Cormedix (CRMD)?
Cormedix (CRMD) 的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cormedix, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cormedix was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Cormedix的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Cormedix的最新评级是在2023年11月15日发布的，因此您应该预计下一个评级将在2024年11月15日左右公布。
Is the Analyst Rating Cormedix (CRMD) correct?
分析师对 Cormedix (CRMD) 的评级正确吗？
While ratings are subjective and will change, the latest Cormedix (CRMD) rating was a reiterated with a price target of $0.00 to $19.00. The current price Cormedix (CRMD) is trading at is $4.09, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但重申了最新的Cormedix（CRMD）评级，目标股价为0.00美元至19.00美元。Cormedix（CRMD）目前的交易价格为4.09美元，在分析师的预测区间内。